"[T]otal gross Medicare spending on the three newest versions of these diabetes medications that have also been recently approved for weight loss -- Ozempic, Rybelsus, and Mounjaro -- has skyrocketed in recent years, rising from $57 million in 2018 to $5.7 billion in 2022.... [T]he combination of intense demand, new uses, and high prices for these treatments is likely to place tremendous pressure on Medicare spending, Part D plan costs, and premiums for Part D coverage."  MORE >>